Critical quality attributes for AAV analysis
Sponsor
In this webinar, we will hear from Phenomenex’s Senior Research Scientist, Shilin Cheung as we delve into chromatography’s vital role in ensuring quality and safety of Adeno-Associated Viruses (AAVs) in drug development. We’ll explore the latest modern chromatographic techniques designed to support AAV quantification and characterization.
Critical quality attributes (CQAs) play a pivotal role in every stage of the drug development process. This session will guide you through the nuances of CQAs, providing a comprehensive understanding of their significance and impact. You'll gain valuable insights into how to navigate common challenges posed by CQAs at various development stages, ensuring that your AAV-based therapies meet the highest industry standards.
As we progress, we'll discuss the importance of selecting fit-for-purpose chemistries and method conditions, specifically tailored to address common CQA tests. These insights are instrumental in ensuring that your analytical methods are robust, efficient, and precise.
- Modern chromatographic approaches for comprehensive quantification and characterization of AAVs
- CQA considerations during different drug development stages
- Fit-for-purpose chemistries and review of method conditions to address common AAV CQA tests
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
